As of Wednesday, February 25, Sangamo Therapeutics, Inc.’s SGMO share price has surged by 14.48%, which has investors questioning if this is right time to sell.

Gilead Sciences to buy biotechnology company, Arcellx for up to $7.8 billion: Foster City, California Wednesday, February 25, 2026, 14:00 Hrs [IST] Gilead Sciences, Inc., a biopha ...

The great surprise of the day was that the Swan River was not aflock with Magpies. Known for hunting silver with a keen eye, these Aussie birds aught to have been greatly interested in the way the low ...

A 33-year-old man died in a freak accident involving a banned kite string, known as 'Chinese manja', highlighting the ongoing issue of its illegal sale in Uttar Pradesh.

Garfield County Sheriff Lou Vallario shared derogatory comments about state Rep. Elizabeth Velasco in an email thread with other members of law enforcement.

USA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next decade, growing from $279.98 billion in 2026 to an estimated $748.17 billion by 2035[1].

The Ethereum Foundation began staking ETH as part of new treasury operations amid a string of sales from co-founder Vitalik Buterin.

With this game not starting until 5.30pm, due to live DAZN television coverage, the Tinners kicked off 11 points from safety and a place lower ...

Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.

Gilead Sciences, Inc. is downgraded to Hold due to uncertainty on the Arcellx acquisition and cell therapy portfolio challenges. Read more on GILD stock here.

Ethereum founder Vitalik Buterin has been selling ETH in the last few days as the second-largest crypto asset continues its fall.

Gilead Sciences agreed to acquire Arcellx in a deal valued at approximately $7.8 billion in total, deepening its push into cell therapy for multiple myeloma.